Status:
RECRUITING
Assessing Optimal XRB Initiation Points in Jail
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use Disorder
Eligibility:
MALE
Phase:
PHASE4
Brief Summary
This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Cor...
Eligibility Criteria
Inclusion
- Incarcerated men able to provide written informed consent in English.\*
- Unsentenced.
- Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.
- Minimum anticipated jail stay is 4 days.
- Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated).
Exclusion
- Sentenced.
- Allergy, hypersensitivity or medical contraindication to either medication.
- Chronic pain requiring opioid pain management or other contraindicated medications.
Key Trial Info
Start Date :
June 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06051890
Start Date
June 2 2025
End Date
March 1 2027
Last Update
September 10 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts University Health Sciences
Boston, Massachusetts, United States, 02111
2
Baystate Health
Springfield, Massachusetts, United States, 01199
3
Middlesex County House of Corrections
New Brunswick, New Jersey, United States, 08902
4
NYU Langone Health - 180 Madison Ave
New York, New York, United States, 10016